Worldwide Tuberculosis (TB) represents a serious health problem. It is estimated that one third of the world is infected with TB and each year approximately 9.5 million people develop active TB infection. These staggering statistics are bad enough, but consider the fact that some of these cases are resistant to drug therapy. The tuberculous bacterium is like any other bacteria and over time has developed resistance to many, and sometimes all, of the currently available drug therapies. Of the above 9.5 million new cases of TB each year about 480,000 are cases of multiple drug resistant TB (MDR-TB). This worldwide health epidemic gets little publicity next to Ebola or Zika virus. The importance of this health issue has not gone unnoticed by governments, including our own. After all, MDR-TB is present in the US, as well as less economically advanced countries. There was a time when world health groups hoped to eradicate TB globally. Current views are less optimistic. Our current administration has set forth a series of goals to be accomplished by 2020. The three goals are: strengthen our ability to treat the disease, increase our international ability and cooperation, and accelerate research especially in the development of a TB vaccine. The one problem with this plan is money. How much are we willing or able to spend and how will we incentivize companies to develop new effective therapies. Until we solve this problem we will not be able to help the 1.5 million in the world who die each year from TB.